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The transmission of malaria by blood transfusion was one of the first recorded incidents of transfusion-transmitted
infections (TTIs). Although the World Health Organization (WHO) recommends that blood for transfusion should
be screened for TTIs, malaria screening is not performed in most malaria-endemic countries in sub-Saharan Africa
(SSA). The transfusion of infected red blood cells may lead to severe post-transfusion clinical manifestations of malaria,
which could be rapidly fatal. Ensuring that blood supply in endemic countries is free from malaria is highly problematical,
as most of the donors may potentially harbour low levels of malaria parasites. Pre-transfusion screening within endemic
settings has been identified as a cost-effective option for prevention of transfusion-transmitted malaria (TTM). But
currently, there is no screening method that is practical, affordable and suitably sensitive for use by blood banks in
SSA. Even if this method was available, rejection of malaria-positive donors would considerably jeopardize the
blood supply and increase morbidity and mortality, especially among pregnant women and children who top the
scale of blood transfusion users in SSA. In this context, the systematic prophylaxis of recipients with anti-malarials
could constitute a good alternative, as it prevents any deferral of donor units as well as the occurrence of TTM.
With the on-going programme, namely the Affordable Medicine Facility - Malaria, there is an increase in the availability
of low-priced artemisinin-based combination therapy that can be used for systematic prophylaxis. It appears
nonetheless an urgent need to conduct cost-benefit studies in order to evaluate each of the TTM preventive
methods. This approach could permit the design and implementation of an evidence-based measure of TTM
prevention in SSA, advocating thereby its widespread use in the region.
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Malaria is a protozoan parasitic infection of humans
resulting from one or more of the five species of the genus
Plasmodium (Plasmodium falciparum, Plasmodium vivax,
Plasmodium ovale, Plasmodium malariae and Plasmo
dium knowlesi) [1]. It is one of the most important
parasitic diseases in the world and remains a major chal-
lenge to mankind. Malaria can be efficiently transmitted
by transfusion of cellular blood components and it is un-
doubtedly responsible for the majority of transfusion-
transmitted diseases in the world [2,3]. But, mainly due to
the high interest in human immunodeficiency virus blood* Correspondence: noubiapjj@yahoo.fr
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stated.safety, transfusion transmission of malaria has been a
neglected topic until recently [3,4]. As a result, there has
been a paucity of information concerning the distribution
and potential role of the different Plasmodium species in
transfusion-related malaria cases, and the clinical impact
of parasitaemic blood in recipients, particularly young
children and pregnant women who are the highest con-
sumers of blood transfusions in sub-Saharan Africa (SSA)
[4,5]. When malaria is transmitted through blood transfu-
sion to a non-immune recipient, it can progress rapidly
and may lead to significant morbidity and mortality, spe-
cifically when diagnosis is delayed [1,3].
The incidence of transfusion-transmitted malaria (TTM)
among people residing in endemic areas is unknown. As a
matter of fact, a substantial proportion of the population inl Ltd. This is an Open Access article distributed under the terms of the Creative
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making it difficult to be sure whether malaria occurring
after blood transfusion was acquired from the transfusion
or not [3,6]. Nonetheless, the World Health Organization
(WHO) recommends that all blood donations should be
screened for malaria where “appropriate and possible”, and
that there should be quality assured testing for transfusion-
transmitted infections (TTIs) [7]. These recommendations
have significant resource implications and have not been
widely implemented by transfusion services in SSA [3,5].
Indeed, there are reasons for the difficulty in screening
blood for malaria in SSA. Severe blood shortages are wide-
spread and would be exacerbated by rejecting blood that
contains malaria parasites [3]. More so, there is currently
no assay to screen blood with low-levels of parasites that is
sensitive, practical and affordable enough for use by trans-
fusion services in endemic countries [3,8]. Hence, there is
no evidence-based guidance to indicate which malaria
screening methods are effective for use by transfusion ser-
vices in malaria-endemic countries or what action should
be undertaken if the donated blood tests positive [3].
Other transfusion guidelines suggest that transfusion
recipients should be given systematic anti-malarial
prophylaxis [3,5,6]. For many years, presumptive anti-
malarial treatment with inexpensive chloroquine was
given to blood recipients to prevent TTM [1,2]. How-
ever, the spread of chloroquine resistance across SSA
has led to such a strategy becoming redundant and ineffect-
ive [1,2]. Alternatives to chloroquine, such as artemisinin
and artemisinin-based combination therapy (ACT) are con-
siderably more expensive, weakening the applicability and
usefulness of anti-malarial prophylaxis in resource-poor set-
tings until latterly [2,3].
Fortunately, a new programme, the Affordable Medicines
Facility - Malaria (AMFm), has recently been put in place
with satisfactory results. This is a pilot supra-national sub-
sidy programme that aims to increase access and affordabil-
ity, therefore, reducing the price of ACT to levels similar to
that of less effective anti-malarials (such as sulphadoxine-
pyrimethamine and chloroquine). The evaluation of this
programme shows that there is an increased availability of
low-priced ACT with no significant variation in availability
based on remoteness [4]. Its implementation in SSA could
thereby reinforce the use of ACT for systematic prophylaxis
of blood recipients in order to efficiently prevent TTM as
well as an unnecessary wastage of blood units, even in re-
mote areas. The present review aims to highlight the bur-
den of TTM in SSA, and discusses the strategies for the
prevention of TTM in these countries.
An overview of the burden of malaria in sub-Saharan Africa
Malaria remains a major public health hazard in SSA owing
to its high morbidity and mortality despite being the focus
of significant financial support and research. According tothe latest World Malaria Report summarizing data received
from 104 malaria-endemic countries and territories, there
were about 219 million cases of malaria and an estimated
660,000 deaths, 90% of which occurring in SSA [5].
Malaria exacts a heavy toll of illness and death among
children specifically the under fives, and on pregnant
women [5]. In fact, most children in endemic areas ex-
perience their first malaria infections during the first
two years of life, when they have not yet acquired ad-
equate immunity, which makes these early years of high-
est risk. Ninety per cent of all malaria deaths in Africa
occur in young children [6]. A child dies every 45 sec-
onds as a result of malaria, the disease accounting for
20% of all childhood deaths [5].
Malaria in pregnancy is widespread. Pregnant women
are highly vulnerable because of iron deficiency, a major
problem in malaria-endemic areas. It endangers the health
of women as well as that of the newborn. Malaria causes
anaemia and low birth weight as a consequence of the loss
of previously existing immunity [7]. Malaria accounts for
6.5% of abortions, 15% of premature deliveries and 0.7% of
deaths in utero [8]. An estimated 200,000 infants die annu-
ally as a result of malaria infection during pregnancy [5].
A contributing factor to the malaria problem in SSA is
the diversity of the parasite that infects humans. Five spe-
cies infect man of which P. falciparum is the most virulent
[8]. These malaria parasites can develop within, invade red
blood cells (erythrocytes) and consume up to 75-80%
of their haemoglobin as nutrient source [6]. Plasmodium
falciparum causes severe complications, such as cerebral
malaria, severe anaemia, acute renal failure, hypoglycaemia
and pulmonary infection [7]. Severe anaemia will occur
when the parasite disrupts the erythrocytes, giving rise to
the necessity of blood transfusion.
Blood transfusion: a life-saving but risky intervention
Every second, someone in the world needs blood [9]. In
every country, surgery, trauma, severe anaemia, and com-
plications of pregnancy are among clinical conditions that
demand blood transfusion [9]. Whatever the degree of de-
velopment of a health care system, transfusion is the only
option for survival for many patients. An adequate supply
of blood is essential for reducing mortality and morbidity
in SSA, especially among young children and pregnant
women [10], but critical shortages are common. For in-
stance, in SSA, 26% of maternal haemorrhage-related
deaths during the period 1970-2007 were due to lack of
available blood for transfusion [11].
Many patients, particularly in SSA, do not have access
to blood when they need it. Of the estimated 80 million
units of blood donated annually worldwide, only 38%
are collected in the developing world where 82% of the
world’s population lives [9]. Up to 150,000 pregnancy-
related deaths could be avoided each year through access
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aria accounts for 70% of all blood transfusions given to
children in SSA [12]. Many children die whilst waiting
for transfusion [12,13]. A Kenyan study found, for in-
stance, that over 60% of children in need of transfusion
may die while waiting for a blood donor [12]. What’s
more, in some Ghanaian regions, nearly 33% of all blood
transfusions given are to infants aged below 3 years [14].
Despite the fact that blood transfusion can be life-
saving, there are associated risks, particularly the trans-
mission of blood-borne infections. Screening for TTIs,
to exclude blood donations at risk of transmitting infec-
tion from donors to recipients, is a critical part of the
process of ensuring that transfusion is as safe as possible.
Effective screening for evidence of the presence of the
most common and dangerous TTIs can reduce the risk
of transmission to very low levels [15]. According to
WHO, regular, voluntary, non-remunerated blood do-
nors from low-risk populations are the foundation of a
safe blood supply [9]. Blood transfusion services should
therefore establish efficient systems to ensure that all do-
nated blood is correctly screened for specific TTIs and
that only non-reactive blood and blood components are
released for clinical and manufacturing use [16].
To be transmissible by blood, the infectious agent
must have the following characteristics: (i) presence in
the blood for long periods, sometimes in high titers, (ii)
stability in blood stored at +4°C or lower, (iii) long incu-
bation period before the appearance of clinical signs,
and (iv) asymptomatic phase or only mild symptoms in
the blood donor, hence not identifiable during the blood
donor selection process [17]. Plasmodium species re-
spond to all the aforementioned criteria [16]. Malaria
can thus be efficiently transmitted by transfusion of cel-
lular blood components.
Prevalence and severity of transfusion–transmitted
malaria
Batista-dos-Santos et al. reported that the history of
TTM dates back to 1882, when Gerhardt empirically
demonstrated the transmission of malaria in humans by
infected blood [18]. However, the first case of accidental
transmission of malaria by blood transfusion was de-
scribed in 1911 [18]. Worldwide, around 3,000 cases of
TTM were reported between 1950 and 1980. These were
predominantly from non-endemic countries, so this is
believed to be a significant underestimate of the global
burden [19].
The prevalence of malaria parasitaemia in African donors
depends on the local endemicity and transmission season
and varies from 0.67% in Nairobi, Kenya, a non-endemic
area, to over 55% in highly endemic northern Nigeria (with
a median prevalence of 10.2%) [20]. Plasmodium species
are the most prevalent transfusion transmissible pathogensespecially in SSA [20]. In fact, among SSA blood donors,
the prevalence of human immunodeficiency virus, hepatitis
C virus and hepatitis B virus ranges from 0.5-16%, 0.5%-
12.3% and 2.5-20% respectively [21].
Given that asymptomatic carriage of malaria parasites is
common in malaria-endemic countries [22], parasitaemia
detected in a blood recipient could have been acquired
from a mosquito bite rather than from the transfused
blood. TTM can consequently only be confirmed by geno-
typing to demonstrate that the parasite in the recipient is
identical to the one in the transfused blood. Studies show
that the frequency of post-transfusion malaria varies from
less than 0.2 cases per million recipients in non-endemic
countries to 50 per million in endemic ones [23].
Anecdotally, Owusu-Ofori et al. [24] conducted a study,
the result of which showed a genotypically confirmed
TTM in only one (2%) of their 50 patients who received a
blood transfusion positive for P. falciparum by polymerase
chain reaction (PCR). The parasite density in the blood
unit that caused the TTM was 280/μL [24]. Another
study from Sudan without performing PCR testing and
genotyping, found that all 12 patients (100%) who re-
ceived malaria-positive blood developed microscopically
confirmed malaria. But the same study also revealed
that two patients (0.52%) developed parasitaemia after
transfusion despite receiving microscopy-negative blood
[25], claiming accordingly that not all cases of malaria oc-
curring after transfusion are transmitted by that transfu-
sion. This last finding has to be taken with caution, given
that without performing PCR testing, the two blood units
could have falsely been declared negative.
Transmission of malaria has been reported to occur
mainly from single-donor products [26]. Any blood
component may harbour viable parasites. Ninety-five per
cent of transfusions in SSA involve whole blood rather
than components [20]. Whole blood and concentrated
erythrocytes represent the most common sources of
TTM; however, some cases of TTM have also been re-
ported after transfusing platelet concentrates, leukocyte
concentrates, cryoprecipitate (contaminated by residual
erythrocytes), and frozen erythrocytes after thawing and
washing. Conversely, transmission through freshly frozen
plasma has not been reported, even though this product
is not of common use in SSA [27,28].
Additionally, in cases of TTM, depending on the num-
ber of parasites in the inoculum, the symptoms of mal-
aria may begin days or weeks after transfusion [29],
presenting as a serious and often fatal disease [30], espe-
cially for non-immune recipients [31]. For instance, as
reported by Freimans et al., as few as ten parasites are
sufficient to initiate fulminant malaria in humans [1].
The majority of recipients of blood transfusions living in
malaria-endemic areas are semi-immune to malaria [32],
but the degree of protection that this immunity confers
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where malaria is endemic who have not had repeated ex-
posure to the parasite may be regarded as non-immune re-
cipients [20] and as a consequence, they may be as
susceptible to TTM as a non-immune person who lives in
a non malaria-endemic country. Besides, pregnant women
and immunocompromized patients, who with young chil-
dren are the biggest demanders of blood transfusions in
Africa, may also be at a high risk of TTM [24]. The clinical
severity of TTM is likely to be very different in malaria-
endemic countries compared to non-endemic ones [20].
The risk of TTM has been associated with the diffi-
culty in identifying infected potential donors, mostly
those with a low number of parasites circulating in their
blood, as well as the ability of this parasite to remain vi-
able in stored blood units, even after the storage process
[27,28]. Thus, the transfusion practice constitutes a
major challenge in malaria-endemic areas because many
potential blood donors are infected. This situation could
jeopardize the attainment of the huge demand for trans-
fusion of blood and blood products in areas where re-
fusal of donation is high, and donation shortages are
frequent [27]. Only a few parasites in a unit of blood are
sufficient to cause infections in susceptible individuals
namely children, pregnant women and immunocompro-
mized patients [20]. TTM presents, therefore, a public
health risk, requiring effective methods of donor screen-
ing [33]. Any malaria screening test used by the transfu-
sion services in SSA needs to be highly sensitive [20,34].
Screening for transfusion-transmitted malaria
The ability to screen blood donations, as well as donors,
can significantly decrease any risk of TTM [27]. Laboratory
screening for malaria remains the possible option for redu-
cing transfusion malaria [23]. There are four specific targets
for donation screening: intracellular parasites, plasmodial
antibodies, plasmodial antigen, and plasmodial DNA [27].
In routine practice, the “gold-standard” technique, op-
tical microscopy in thick blood smears, is the most often
used for Plasmodium detection in malaria-endemic areas
[18]. This technique is considered the most effective and
inexpensive for the diagnosis of malaria [18]. Its sensitiv-
ity varies depending on the expertise of the microscopist.
In experienced hands, sensitivities of 5-50 parasites/μL
can be achieved, but in routine practice most laboratories
achieve a lower sensitivity of around 500 parasites/μL
[35,36]. Further, a single parasite identified by microscopic
evaluation of a thick blood film (4 mL) is equivalent to al-
most 10,000 parasites in a 450 mL unit of blood [20]. But
despite their continued application as key diagnostic tests,
microscopy techniques have some major limitations that
render them inappropriate for universal or targeted donor
screening. Precisely, they lack the required sensitivity
and specificity to detect all infected units, specifically insituations of low parasite density, hence presenting a
real transfusion risk for the recipient [18,27]. In
addition, they are time-consuming (generally requiring
one hour or more for preparation and detailed examin-
ation), are inadequate for examining a large volume of
samples, and do require considerable expertise and spe-
cialized equipment when fluorescent methods are used
[27,37,38]. This hinders a rapid evaluation, particularly
in a blood transfusion service. Finally, post-transfusion
malaria cases have been reported in recipients of blood
that has been tested negative by microscopy [25]. Mi-
croscopy detection of malaria parasites is consequently
likely to significantly underestimate the prevalence of
parasitaemia in blood donations, and appears not sensi-
tive enough to be recommended as the suitable screen-
ing test for transfusion services in SSA malaria-endemic
settings [20].
Alternative methods have been developed for the
screening of malaria for use both in areas where malaria
is endemic and in areas where it is not, detecting specific
Plasmodium antigens or antibodies directed against the
Plasmodium. The detection of malarial antigen with
rapid diagnostic tests (RDTs) was originally intended as a
more rapid and objective alternative to direct microscopy
[27]. RDTs detect Plasmodium-specific parasite proteins,
such as pan-malarial lactate dehydrogenase (pLDH), and
P. falciparum specific histidine-rich protein 2 (HRP2).
Most of these assays are in a ‘dipstick’ format that can be
used with minimal training, are field applicable, and pro-
vide a result within 10-20 minutes [27,33,39]. However,
RDTs methods have not offered improved sensitivity over
microscopy, and their sensitivity decreases as parasitaemia
falls below 100 parasites/μL. Also, false positives are ob-
served, especially after treatment, as the parasite antigens
detected can remain in the circulation following parasite
clearance, this being especially the case for the HRP2
antigen-based tests. Eventually, current RDTs are either
specific to P. falciparum, or they cannot distinguish
between the parasite species present [33,35]. Heutmekers
et al. using a RDT CareStart pLDH showed for instance
that overall sensitivity for P. falciparum and P. vivax was
good, but poor for P. ovale and P. malariae [40]. In
order to increase the likelihood to detect all types of
Plasmodium species, it has been proposed a combined
HRP2/pLDH-based RDT [41]. Heutmekers et al. showed
on another hand that false-negative results mainly oc-
curred at parasite density less than 100/μL [40]. Atchade
et al. claimed that the pLDH-based RDT can exhibit a de-
tectability threshold of 1 parasite/μL, lower than that of
the other methods, with the exception of PCR, and that
unlike HRP2-based tests, false positives are exceptional
with pLDH-based RDTs [42]. Based on these findings, the
pLDH antigen detection for Plasmodium species could be
an interesting tool for blood donation qualification in
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[30,42]. It has been noticed nonetheless that seasons influ-
enced pLDH prevalence. What’s more, if the donors had
taken self-treatment measures prior to blood donation
such as drugs or herbal teas, malaria infection was masked
and pLDH detection failed [42].
Following infection with Plasmodium species, the im-
mune response results in the formation of specific anti-
bodies not necessarily protective, and not necessarily
indicating that the person is harbouring malaria para-
sites as well [43]. Antibody detection assays demonstrate
high antibody levels and good sensitivity in semi-
immune individuals, the very donors who are potentially
at high risk of acting as a source of TTM by being
asymptomatic but parasitaemic [43]. After having com-
pared the IFAT assay with the DiaMed ELISA malaria
antibody test, Ehghouzzi et al. showed that the latter
was more sensitive and specific than the former, with a
possibility of automation, fulfilling thereby the criteria of
a satisfactory and reliable malaria screening test [44].
However, a negative malarial antibody test cannot guar-
antee that the donor is not infected with malaria para-
sites, as the antibodies may not be detectable in the first
few days of malarial illness, and infection with P. ovale
and P. malariae may not be detected by P. falciparum
and P. vivax antigen-based assays [43]. Given the poten-
tial for malaria parasites to persist in certain patients for
some years, it is worth noting that in individuals who
have suffered repeated attacks of malaria, anti-malarial
immunoglobulins may be detectable for several years.
Even though the persistence of antibodies long after cure
of the malarial infection would lead to some individuals,
who are no longer parasitaemic, to be excluded as potential
blood donors, it does provide a useful margin of safety if
candidate donors, who are malaria-antibody positive, are
excluded from donating [43]. Malaria antibody tests are
therefore useful in non-endemic areas where they will re-
sult in rejecting blood donation in case of positivity, but
these assays are of no use in malaria endemic areas. Indeed,
malaria antibody prevalence is very high: 87% in Benin,
and 65.33% in Senegal [30,42]. This would lead to a high
rate of blood donor deferral as most of the populations in
endemic zones harbour anti-malarial immunoglobulins.
Methods based on molecular biology have been used
to detect different types of Plasmodium by PCR, such as
the nested PCR [45]. This technique is based on the
amplification of a fragment of the small subunit riboso-
mal RNA of the parasite and has been used for the diag-
nosis of malaria for research purpose and reference
laboratories [38,46,47]. The PCR technique can detect
parasites below the threshold levels of microscopy. In-
deed, when performed under optimal conditions, PCR
can detect parasitaemia as low as 0.004 to 1 parasite/μL
of blood [27,46,47]. However, the result directly dependson the quality of the genetic material (DNA) of the para-
site obtained during extraction and amplification, and on
the quality of the reagents. Furthermore, the test is very
expensive, requires extensive training and a long analysis
time [18,23,27], restricting thereby its usage as a routine
diagnostic test for malaria in SSA laboratories or blood
banks [38,47-49]. Real-time PCR is considered at the mo-
ment to be the best molecular biology technique for the
diagnosis of malaria [18,38,48,50]. It prevents ambiguous
results because it does not require agarose gels, minimizes
manual work, reduces pipetting errors, performs well
under high throughput, and provides quantitative results
of parasite density [38]. Batista-dos-Santos et al. have de-
scribed real time PCR as a necessary, appropriate and in-
expensive method, with higher sensitivity and specificity
compared to those previously described, which can be
adopted as part of the laboratory screening in haemother-
apy centres, especially in malaria-endemic areas [18].
Owing to its prohibitive cost as well as the fact that the
infrastructure needed is scarcely available in SSA malaria-
endemic zones, which by the way are almost all resource-
limited settings, PCR is not currently, or in the foreseeable
future, a viable alternative for the screening of blood do-
nations [27]. PCR may be probably best used in a stepwise
fashion when other testing modalities are non-diagnostic
but when the index of suspicion for malaria is high [33].
A recently available technique based on detection of hae-
mozoin pigment in white blood cells by automated haema-
tology cell counters has been described as a convenient,
less costly and objective malaria screening method [23,51].
According to the review from Campuzano-Zaluaga et al.,
the accuracy for malaria diagnosis using automated haema-
tology analysis may vary according to species, parasite load,
immunity and clinical context where the method is applied
[51]. Its overall sensitivity ranges from 48.6% to 100%, and
its specificity, from 25.3% to 100%. The sensitivity has been
shown to decrease down to 50% with parasitaemia of less
than 0.1%. Another factor tempering automated haematol-
ogy analysis utilization is that laboratory staff ought to re-
ceive appropriate and continuous training allowing them
to recognize malaria-related changes during validation of
cell blood count results [51].
Apart from laboratory screening, donor questioning has
also been proposed as another tool for malaria screening
in order to lessen the risk of TTM. It aims at deferring all
potential blood donors who have experienced a febrile epi-
sode at least three months before blood donation. But this
strategy lacks the capacity of eliminating asymptomatic
but malaria-parasitaemic blood donors [30,42]. To be use-
ful, the medical selection through donor questionnaire
must be integrated in an algorithm including other scree-
ning tools [33].
Overall, a number of factors need to be considered in
selecting the most appropriate assays. In general, a balance
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sources available, including finances, staff and their level
of expertise, equipments, consumables, and disposables
[16]. Each screening system has its advantages and limita-
tions that should be taken into consideration when select-
ing assays. Some limitations include: (i) the length of time
following infection before the screening test becomes re-
active (window period), (ii) rates of biological false posi-
tives which may result in the wastage of donations and
unnecessary deferral of donors, and (iii) the complexity of
some systems that require automation [16].
According to WHO guidelines, the minimum evalua-
ted sensitivity and specificity levels of all assays used for
blood screening should be as high as possible and pref-
erably not less than 99.5% [16]. But, we have seen from
what precedes that the sensitivity of the most currently
used methods for malaria detection in SSA blood units
is much lower than this required threshold, so as to de-
tect level of parasitaemia capable of causing TTM (ap-
proximately 0.00004 parasites/μL or 1-10 parasites/unit
of blood) [20]. In fact, Owusu-Ofori et al. after perform-
ing thick blood films, RDT, enzyme immunoassays and
real time PCR for malaria screening of blood donor
units concluded that none of these four tests would be
ideal for African blood banks to be used for the preven-
tion of TTM, as they were either insufficiently sensitive
or too sensitive for malaria parasites detection in blood
donor units [24].
Pre-transfusion screening of donor blood units and
systematic anti-malarial prophylaxis for recipients: which
one is the most cost-effective strategy to lessen the risk
of transfusion-transmitted malaria in sub-Saharan Africa?
The transfusion practice constitutes a major challenge in
malaria-endemic areas because many potential blood do-
nors are infected. Identifying low-risk individuals is vir-
tually impossible. International policies recommend that
all blood donations should be screened for malaria
where “appropriate and possible [16], but this is not of
routine practice in SSA. It has clearly been figured out
that routine screening of all donated blood would effi-
ciently prevent infected blood donations especially when
the risk of TTM appears relatively high, hence a reduc-
tion in Plasmodium transmission particularly in critical
patients, such as children and pregnant women [42,52].
A good screening tool for malaria detection in blood
units must have a high sensitivity, a high positive pre-
dictive value; it must be capable of recognizing all the
Plasmodium species, must be rapid and less costly.
Moreover, it must enable a reduction of TTM risk as
well as that of falsely deferred blood donors [29,30]. But,
to date, there is no test to screen blood units for low-
level parasitaemia that is sensitive, practical and affor-
dable enough for use by transfusion services in endemiccountries [2,20,24]. Some test are insufficiently sensitive
(optical microscopy and RDTs) while others are too sen-
sitive or cost-prohibitive (antibody detection tests and
PCR) [20]. It is true nonetheless that pLDH-based RDTs
have been advocated as a valid tool for malaria screening in
blood banks of malaria-endemic settings, as they were able
to detect at least one parasite/μL [30,42]. But there has not
been any cost-benefit analysis to support this recommenda-
tion, and Ansah et al. found that it was less clear if re-
placing microscopy with RDT-based diagnostics should be
recommended on cost-effectiveness grounds [39].
So, there is not any current “realistic” and suitable
method to screen for malaria parasites in blood units.
And even if this method was available, there is no
evidence-based policy indicating what action should be
taken if the donated blood is tested positive, bearing in
mind that in some regions almost 55% of blood units
contain malaria parasites [20]. Thus, rejection of malaria-
positive donors would substantially jeopardize the blood
supply in a context where critical shortages and refusal
of blood donations are common [9-11,42]. After pro-
posing pLDH as a suitable tool for malaria screening,
Atchade et al. note however that the feasibility of
rejecting positive blood donations with regard to blood
availability in malaria-endemic areas remains a serious
problem [42]. Such rejection will result undoubtedly in
an increased morbidity and mortality, predominantly
among women and children [16]. For instance, Rajab
et al. have shown that if malaria-positive donor units
were to be excluded from the Kenyan national blood
supply, an estimated 5% of blood units (compared to
1.3% for HIV, 3.6% for hepatitis B virus and 1.3% for
hepatitis C virus) would be wasted [23]. The wastage
would be more enormous in northern Nigeria where
the prevalence of malaria in blood donations reaches
almost 55% [20].
Pre-transfusion screening will lead thus to the detec-
tion of malaria-positive blood units that will be after-
wards unfortunately rejected. In order to prevent
unnecessary deferral of potential blood donors as well as
rejection and substantial wastage of malaria-positive
donor units, many authors, as well as WHO, advocate
appropriate and effective malaria prophylaxis to be ad-
ministered with every transfusion especially in highly en-
demic areas [2,16,20,23,24,27]. Anti-malarial prophylaxis
with every donation allows for an increase in blood sup-
ply, as malaria-positive units are still available for trans-
fusion. This prophylaxis used affordable chloroquine or
sulphadoxine-pyrimethamine (SP). But since chloroquine
resistance became widespread in SSA, it has recently been
replaced by more expensive ACT, increasing the cost of
treating all transfusion recipients with anti-malarials by al-
most ten-fold and making this practice cost-prohibitive
and unaffordable on a wide scale [1,2,20,23].
Table 1 Summary of recommendations from published
studies advocating the reduction of transfusion-transmitted
malaria in malaria endemic areas
Recommendation
Screening
Blood donation policies should incorporate
malaria screening
Donors should be screened for malaria before
donation
Blood for neonates should be screened for malaria
Deferral/retention
All blood infected with malaria should be rejected
Blood screened for malaria should be retained but




Anti-malarials should be added to donated blood
to eradicate parasite in vitro
Photochemical inactivation of parasites with
amotosalen and long-wavelength ultraviolet light
in platelet and plasma components
All neonates should be treated after every
transfusion
All recipients of malaria-infected blood should be
treated for malaria
Presumptive treatment for all recipients
From Owusu-Ofori et al. [3].
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prevented of transfusion-associated malaria is consider-
ably higher for recipient anti-malarial prophylaxis than
pre-transfusion screening using an automated flow cy-
tometry technique [23]. Anecdotally, a cost analysis
undertaken by Rajab et al. in 2005 showed a cost per
case prevented of US$1.4 in adults and US$0.69 in
paediatrics for the option of recipient prophylaxis using
a SP-based drug. The cost escalated to US$7.79 in adults
and US$5.84 in paediatrics if the prophylaxis was
upgraded to the recommended ACT. For the option of
pre-transfusion screening using an automated technique,
the cost was US$0.03 [23]. However, it is notable that
the initial cost of the equipment for that automated
technique may appear prohibitive, and the technique is
susceptible to miss early infections and may also record
false positives even after parasitaemia clears [23]. Like-
wise, Owusu-Ofori et al., based on the low incidence of
TTM they found, concluded that malaria transmission
occurs infrequently, suggesting that routine treatment
for all recipients of blood transfusion may probably be
unnecessary [24] whilst considering that inappropriate
drug use may consistently contribute to the appearance
of drug resistance [23].
Happily, there is an emerging programme that can help
to reinforce the practice of malaria prophylaxis by consid-
erably lowering the price of ACT. This is the AMFm. It is
a “factory-gated” subsidy for ACT launched in 2010 and
currently being piloted in seven African countries. The
goals of the AMFm are to increase the availability and
reduce the prices of ACT to levels similar to that of less
effective anti-malarials, and to displace artemisinin mo-
notherapy whose widespread availability and improper
use threaten to accelerate parasite resistance to artemisinin.
A recent evaluation of this programme in Tanzania showed
that average ACT prices for an adult dose fell from US
$1.03 to 0.81 within six to eight months (this price being
cheaper for paediatric doses), as well as it has led to a large
increase in availability of the drugs with no significant vari-
ation in availability based on remoteness [4].
Furthermore, governments of some SSA countries such
as Cameroon have decided to give ACT to children under
five years old free of charge, and have subsidized adult
doses. This strategy could also contribute in reinforcing
malaria prophylaxis for blood recipients as an affordable
policy given that most of the recipients in SSA are young
children. In parallel, a recent study showed that almost
50% of blood recipients have received a malaria treatment
with their blood transfusion, 84% of which were children,
and in almost 80% of cases the anti-malarials were pre-
scribed at the same time as the blood transfusion [2]. In
malaria-endemic areas, anti-malarials are given presump-
tively on the basis that most febrile children presenting
with severe anaemia have underlying malaria and thatthey are at high risk of TTM [2,24,27]. It appears prefer-
able in such cases to presumptively treat the other 50%
of recipients for whom the malaria treatment was not
yet ordered, without performing any screening test be-
fore the transfusion.
Alternatives to donor screening for reducing the burden
of TTM have been published (see Table 1), even though
for most of them their implementation is cost-prohibitive.
These include adding anti-malarials to the blood pack,
marking units that test positive for malaria, and only
screening blood destined for neonates [20]. There are also
additional strategies that can be implemented, depending
on the geography of the country, the periodicity of malaria
(seasonal or year round), the type and age of the donors,
and the age, gender and underlying condition of the recip-
ients, together with their existing malaria status. For ex-
ample, the algorithm recently proposed by Sobani et al. in
Pakistan is mainly based on the aforementioned strategy
[33]. Finally, some promising new technologies are forth-
coming, such as pathogen reduction measures that have
the potential to reduce TTM with P. falciparum being
highly sensitive to inactivation by photochemical treat-
ment with amotosalen and long wavelength ultraviolet
light [20]. But this strategy is not yet implemented even in
Northern countries, and its feasibility in SSA is question-
able, as this technique is not cheap and requires trained
personnel as well as sophisticated equipments. Should it
be possible to reduce its cost, the additional benefit of pre-
venting the transmission of other pathogens present in the
African blood supply would be considerable.
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ferent strategies adopted, it is virtually impossible to
safeguard the blood supply from malaria in endemic
countries, and often the transfusion of blood, together
with the judicial use of anti-malarial drugs, is necessary
to minimize the occurrence of TTM in the recipient. In
addition, promoting the appropriate clinical use of blood
has a role in minimizing TTM by ensuring that patients
receive blood only when needed and, therefore, are not
exposed unnecessarily [27]. Finally, it appears as an ur-
gent need to perform cost-benefit analysis of the differ-
ent screening tools for malaria detection in blood units,
so as to identify which method is the most cost effective
to be implemented as the gold standard for malaria
screening of blood units in order to lessen the risk of
TTM, especially in SSA malaria-endemic regions.
Conclusion
The critical lack of evidence about the clinical impact of
TTM and the absence of an effective and feasible screen-
ing method are impediments to rational decision-making
about when and how to screen blood for malaria. There
are no screening tools for malaria that are practical, af-
fordable, and suitably sensitive for use by blood banks in
SSA. The prevalence of malaria in blood donors is variable
but can reach 55% in some parts of West Africa. Im-
plementation of any policy that advocates deferral of all
such donors will have a significant negative impact on the
availability of blood for transfusion, will undoubtedly in-
crease mortality particularly among pregnant women and
children, and must be underpinned by robust evidence.
With the availability of subsidized and low-priced ACT,
the anti-malarial prophylaxis with every transfusion ap-
pears a practical alternative strategy to lessen TTM in
SSA. However, cost-benefit studies should be conducted
to point out the most suitable method to be used for the
prevention of TTM. One should however bear in mind
that complete prevention of TTM may not be attainable,
so malaria must always be considered in any patient with
a febrile illness post-transfusion.
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